Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBIT: 2009-2021

Historic EBIT for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to -$85.5 million.

  • Avadel Pharmaceuticals' EBIT fell 62.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$85.5 million, marking a year-over-year decrease of 1571.13%. This contributed to the annual value of -$85.5 million for FY2021, which is 1571.13% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported EBIT of -$85.5 million as of FY2021, which was down 1,571.13% from $5.8 million recorded in FY2020.
  • Avadel Pharmaceuticals' EBIT's 5-year high stood at $89.5 million during FY2017, with a 5-year trough of -$104.9 million in FY2018.
  • Its 3-year average for EBIT is -$34.6 million, with a median of -$24.1 million in 2019.
  • Its EBIT has fluctuated over the past 5 years, first spiked by 1,902.72% in 2017, then slumped by 1,571.13% in 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' EBIT (Yearly) stood at $89.5 million in 2017, then slumped by 217.23% to -$104.9 million in 2018, then spiked by 77.02% to -$24.1 million in 2019, then skyrocketed by 124.12% to $5.8 million in 2020, then plummeted by 1,571.13% to -$85.5 million in 2021.